SOAR Trial, A Two-part Study: Interventional Phase II Single-arm Trial to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia, and an Extension With up to 60-months Follow-up

Trial Profile

SOAR Trial, A Two-part Study: Interventional Phase II Single-arm Trial to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia, and an Extension With up to 60-months Follow-up

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Ciclosporin (Primary) ; Eltrombopag (Primary)
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Acronyms SOAR
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 19 Aug 2023 to 4 Sep 2023.
    • 06 Dec 2017 Planned primary completion date changed from 19 Aug 2023 to 4 Sep 2023.
    • 18 Sep 2017 Planned End Date changed from 11 Jul 2023 to 19 Aug 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top